Trial Protocol GlobiFer - Oral Iron Repletion

Oral Iron Repletion With Globifer Forte® After 12 Weeks of Treatment

The haemoglobin level of the patients with iron deficiency should be increased clinical relevant after 12 weeks treatment with GlobiFer Forte.

Inclusion Criteria:

1. ≥ 18 ≤ 60 years of age
2. Signed written informed consent
3. Hb ≥ 8 ≤ 10g/dl for
4. Female

Exclusion Criteria:

1. History of acquired iron overload, known haemochromatosis or first relatives with haemochromatosis, and allergic disorders (asthma, eczema, and anaphylactic reactions).
2. Known hypersensitivity to oral iron preparations.
3. Diseases, which an iron supplementation is not allowed or contraindicated.
4. Patients on current oral or intravenous iron supplementation
5. History of erythropoietin therapy in previous 30 days or scheduled for erythropoietin therapy or blood transfusion during duration of the study.
6. Patients who have had iron supplementation within the last 30 days.
7. Other reasons which in the investigator's judgment argue against inclusion of the patient into the trial.
8. Inability to comprehend study protocol
9. Participation in another clinical trial (currently or within the last 30 days)